Class action lawsuits
A class action lawsuit has been filed against Novo Nordisk A/S, a Danish multinational pharmaceutical company, alleging violations of federal securities laws. The lawsuit, filed by Bronstein, Gewirtz & Grossman, LLC, seeks to recover damages for investors who purchased Novo Nordisk securities between May 7, 2025, and July 28,
Class action lawsuits
The Gross Law Firm has issued a notice to shareholders of Novo Nordisk A/S (NYSE: NVO) who purchased shares during the class period of May 7, 2025 to July 28, 2025. The firm is investigating claims that defendants made false and misleading statements to investors about the company'
Class action lawsuits
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, has notified investors of a class action lawsuit filed against Novo Nordisk A/S ("Novo Nordisk") and certain of its officers. The lawsuit seeks to recover damages for alleged violations of the federal securities laws on behalf of
Class action lawsuits
The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Novo Nordisk A/S (NYSE: NVO) securities between May 7, 2025 and July 28, 2025, both dates inclusive, of the important September 30, 2025 lead plaintiff deadline. Investors who purchased Novo Nordisk securities during this period
Class action lawsuits
Novo Nordisk A/S, a leading healthcare company, is embroiled in a securities class action lawsuit filed on behalf of investors who purchased or acquired the company's securities between May 7, 2025, and July 28, 2025. The lawsuit alleges that the company's defendants made misrepresentations concerning
Class action lawsuits
Investors who purchased Novo Nordisk securities between May 7, 2025, and July 28, 2025, may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. A class action lawsuit has been filed against Novo Nordisk A/S (NYSE: NVO) due to allegedly misleading
Class action lawsuits
Pomerantz LLP has announced a class action lawsuit against Hims & Hers Health, Inc. (HIMS) regarding securities fraud and unlawful business practices. The lawsuit concerns allegations that Hims & Hers and its officers or directors have engaged in deceptive promotion and sales of counterfeit versions of the FDA-approved medication Wegovy.
Class action lawsuits
Stockholders of Novo Nordisk A/S, a healthcare company focused on research, development, manufacturing, and distribution of pharmaceuticals, are being reminded of a class action lawsuit filed on their behalf regarding alleged misrepresentations of revenue and profit growth potential. The complaint, filed between May 7, 2025, and July 28, 2025,
Securities law
Investors who suffered losses in Novo Nordisk's stock between May 7 and July 28, 2025, are reminded of the September 30, 2025, deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that the company and its executives made false and misleading statements
Class action lawsuits
Investors who purchased Hims & Hers Health, Inc. securities between April 29, 2025, and June 23, 2025, are reminded of the upcoming deadline to file a lead plaintiff motion in the class action lawsuit. The lawsuit alleges that Hims made materially false and/or misleading statements about its business, operations,
Securities law
Investors who suffered losses exceeding $100,000 in Novo Nordisk A/S between May 7, 2025, and July 28, 2025, may be eligible to discuss their options with lead securities litigation partner James (Josh) Wilson of Faruqi & Faruqi, LLP. The firm is investigating potential claims against Novo Nordisk, alleging
Securities law
Faruqi & Faruqi, LLP is investigating claims against Hims & Hers Health, Inc. (HIMS) for allegedly making false and/or misleading statements and/or failing to disclose that the company was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy." This led to a
